Document:

Supply and License Agreement

 Exhibit 10.11 
  
 SUPPLY AND LICENSE AGREEMENT 
  

This Supply and License Agreement (“Agreement”) is made and entered into this 5th day of March, 1999, by and between Dade Behring Inc.,
(“Dade Behring”) a Delaware corporation with a principal place of business at 1717 Deerfield Road, Deerfield, Illinois 60015 and HemoSense, Inc., a Delaware corporation (“HemoSense”) having a principal place of business at 2157
O’Toole Avenue, Suite H, San Jose, California. 
  
 WHEREAS,
Dade Behring is a manufacturer of diagnostic products which includes products containing a truncated form of recombinant human tissue factor (“rTF”); 
  

WHEREAS, Dade Behring is a licensee of the [***]/[***] Universities patent application and the Genetech patent and patent application and a sublicensee
of the [***] patent and patent applications covering various forms of (“rTF”); 
  
 WHEREAS, Dade Behring and HemoSense desire to enter into a corporate partner
relationship wherein Dade Behring will (i) manufacture rTF for HemoSense, (ii) grant HemoSense a license to sell the Point of Care Product (as defined below); (iii) Dade Behring will have an option to distribute HemoSense’s Point of Care
Product (as defined below) and (iv) become an equity owner in HemoSense; 
  
 NOW, THEREFORE, for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged the parties hereto agree as follows: 
  

	I.	Definitions 

  

	 	a.	The term “Point of Care Product” shall mean that prothrombin time test currently being designed, and developed, by HemoSense under the name of “Comet” for the
point of care or self test market. 

  

	 	b.	The term “Certificate of Analysis” shall mean a certificate of analysis for the rTF, which shall include specific information and values for each shipment in substantially
the form set forth in Schedule A. 

  

	 	c.	The term “Specifications” shall mean those specifications for rTF set forth on Schedule B. 

  

	 	d.	The term “Patents” shall mean the following United States patents and applications and their foreign counterparts: U.S. patent application Serial No. [***] filed [***],
which is a continuation in part of U.S. patent application Serial No. [***], filed [***], which is a continuation in part of U.S. patent application Serial No. [***], filed [***], (now abandoned) and U.S. patent 

 *** Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.*** 
  

 application Serial No. 70/305,409 filed April 7,1987 and Serial No. 07/013,743 filed February 12,1987 as
well as any continuations. 
  

	 	e.	The term “HemoSense Customer” shall mean any person or entity who purchases the Point of Care Product directly from HemoSense. 

  

	 	f.	The term “Standard Cost” shall mean the amount set forth on Schedule C. 

  

	 	g.	The term “Delivery Date” shall mean the date set forth in the HemoSense purchase order which shall be on or after the April 1 of the year following the order.

  

	 	h.	The term “Net Revenues” shall mean sales net of taxes, insurance, shipping, returns and rebates. 

  

	II.	Supply 

  

	 	2.01	Requirements. Dade Behring shall supply to HemoSense and HemoSense shall buy from Dade Behring HemoSense’s requirements for rTF. HemoSense shall provide Dade Behring
with a rolling two (2) year forecast for rTF each June 30th, beginning on June 30, 1999. Each October 1, beginning on October 1,1999, HemoSense shall send a firm purchase order for rTF to Dade Behring for the following
year. Dade Behring will deliver the ordered rTF within six (6) months of receipt of the purchase order. Dade Berhing shall not be required to deliver, in any particular year, more than [***] ([***]%) percent of the HemoSense forecast for that year.
Dade Behring will use commercially reasonable efforts to supply additional amounts of rTF requested by HemoSense over [***]% of the forecast. 

  

	III.	Payment 

  

	 	3.01	Prices. Dade Behring shall sell rTF to HemoSense at Dade Behring’s Standard Cost plus [***] ([***]%) percent (the “Price”). Every January 1st, Dade Behring shall have the right to raise the Price of rTF at least commensurate with the medical CPI-U, if Dade Behring
raises the Price above the CPI-U, HemoSense shall have the right to audit such increase to be certain that such increase represents Dade Behring’s new Standard Cost. Prices are FOB, HemoSense Inc., San Jose, CA. 

  

	 	3.02	Invoices. Dade Behring shall invoice HemoSense for the rTF and HemoSense shall pay all invoices within thirty (30) days of receipt thereof. 

  

 *** Confidential treatment
requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. 
  

 2 

	 	3.03	Order Terms. In the event of conflict between this Agreement and any HemoSense purchase order or Dade Behring invoice, the terms of this Agreement shall prevail over the
order or invoice. 

  

	IV.	Packaging/Delivery 

  

	 	4.01	Packaging. Dade Behring shall package and ship the rTF in packaging sufficient to maintain the physical and chemical integrity of the rTF. 

  

	 	4.02	Shipments. Dade Behring shall ship all orders for rTF by air courier to HemoSense’s San Jose facility (or such other facility as HemoSense may reasonably designate in
writing from time to time) on or before the Delivery Date set forth in the order. HemoSense shall pay all costs of such shipment and insurance. 

  

	 	4.03	Notification of Damages. HemoSense shall notify Dade Behring of any physical loss or damage to the rTF within fifteen (15) days of receipt thereof. 

 

	V.	rTF Quality 

  

	 	5.01	Certificate of Analysis. Dade Behring shall provide HemoSense with a Certificate of Analysis for each order shipped to HemoSense together with such shipment.

  

	 	5.02	Specifications. Dade Behring warrants and represents that the rTF are manufactured and packaged in accordance with all federal and state statutory and agency requirements and
that each order of rTF shall meet the Specifications. 

  

	 	5.03	 rTF Acceptance. HemoSense shall test each order of rTF within [***] ([***]) days of receipt of that order, to determine if the rTF meet the Specifications.
Promptly after such testing, HemoSense shall notify Dade Behring in writing if the rTF does not conform to the Specifications. Upon receipt of such notification, Dade Behring shall retest the rTF and promptly advise HemoSense of the results of the
retest. If Dade Behring agrees that the rTF is nonconforming, Dade Behring shall replace the nonconforming rTF at no cost to HemoSense. In the event that it is necessary to replace an order or any part thereof of rTF, Dade Behring shall deliver a
replacement order or part thereof to HemoSense within [***] ([***]) days from the date that the nonconforming rTF was acknowledged by Dade Behring. If Dade Behring and HemoSense 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 3 

	 	 
do not agree on the test results, the parties shall make good faith efforts to amicably resolve their differences. 

  

	 	5.04	Notification of Manufacturing Changes. Dade Behring agrees to notify HemoSense in writing prior to implementing any change in the Specifications or in the key steps required
for processing the rTF, and to provide HemoSense with a sample of rTF containing the proposed change. Within [***] ([***]) days after notification or, if applicable, after receipt of a sample of the revised rTF, HemoSense will notify Dade Behring in
writing whether the intended change is acceptable. If the change is unacceptable. Dade Behring will manufacture a final lot of rTF (up to the amount forecasted for that year) and then HemoSense shall have the right to terminate this Agreement

  

	 	5.05	Revisions to Specifications. HemoSense may request revisions of the Specifications to obtain better performance of the rTF in connection with the HemoSense Point of Care
Product. If such revised specifications are not acceptable to Dade Behring, in its sole discretion, or if the parties cannot agree on a revised price commensurate with the revised specifications for rTF, then HemoSense will purchase all raw
materials and inventory already purchased or manufactured by Dade Behring pursuant to the HemoSense forecast for that year. 

  

	VI.	Warranties/Representations/Indemnification and Insurance 

  

	 	6.01	Dade Behring as Supplier. Dade Behring warrants and represents that it has the right to sell the rTF to HemoSense. 

  

	 	6.02	Indemnification by HemoSense. HemoSense shall defend, indemnify and hold Dade Behring harmless from and against any and all loss, including court costs and reasonable
attorneys’ fees and expenses, arising out of any governmental or private actions based upon HemoSense’s manufacture, promotion, or sale of Point of Care Products, except for (a) loss arising out of the claims, liabilities, or suits set
forth in Section 6.03 below, which shall be indemnified in accordance with the provisions of that Section, and (b) claims resulting from Dade Behring’s gross negligence or other wrongdoing. 

  

	 	6.03	Intellectual Property Indemnification. 

  

	 	(a)	 Dade Behring shall indemnify, defend, and hold HemoSense harmless from and against any claim, liability, or suit brought by a third party alleging that any rTF as
purchased by HemoSense 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 4 

	 	 
hereunder (but not as used in combination with the Point of Care Product) infringes the intellectual property (including, but not limited to patent and trade
secret rights) owned by or licensed to such third party. 

  

	 	(b)	HemoSense shall indemnify, defend, and hold Dade Behring harmless from and against any claim, liability, or suit brought by a third party alleging that the use of rTF in combination
with the HemoSense Point of Care Product or any HemoSense product infringes the intellectual property (including, but not limited to patent and trade secret rights) owned by or licensed to such third party except to the extent that any claim or
lawsuit is covered by 6.03(a). 

  

	 	6.04	Indemnification Notice. The rights provided in Sections 6.02 and 6.03 shall be contingent upon the providing of prompt, reasonable notice of any such claim to the
indemnifying party and providing the full opportunity to such party to defend and settle such claims by counsel of such party’s choosing. In no event shall Dade Behring be liable for consequential, punitive or special damages.

  

	 	6.05	Insurance. Prior to the first sale of the Point of Care Product, HemoSense agrees to procure and maintain general comprehensive liability insurance covering each occurrence
of bodily injury and property damage in the amount of not less than [***] Dollars (US$[***]) per occurrence and [***] Dollars (US$[***]) in the aggregate with endorsements for product and completed operations, blanket contractual liability, and
broad form vender’s liability. Upon the request of Dade Behring, HemoSense shall on or before shipment of any rTF hereunder furnish to Dade Behring a certificate of insurance evidencing the foregoing coverages and limits and providing that such
insurance shall not be cancelable without at least thirty (30) days prior written notice to Dade Behring. 

  

	 	6.06	Disclaimer. EXCEPT FOR THE WARRANTIES CONTAINED IN THIS AGREEMENT, DADE BEHRING EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES WHETHER EXPRESSED OR IMPLIED AND ALL WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

  

	VII.	License 

  

	 	7.01	 Grant of License. Dade Behring hereby grants to HemoSense and HemoSense hereby accepts from Dade Behring a worldwide royalty-bearing right and sublicense
under the Patents to use the 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 5 

	 	 
rTF in the HemoSense Point of Care Product and to make, have made, sell or have sold the Point of Care Product for a term of five (5) years. HemoSense shall
have no right of sublicense. 

  

	 	7.02	Royalty. HemoSense shall pay to Dade Behring on a quarterly basis a royalty on the Net Revenues of the Point of Care Product made to a HemoSense Customer based upon the
following schedule: 

  

			
	[***]% up to	  	$[***] cumulative sales
		
	[***]%	  	$[***] cumulative sales
		
	[***]%	  	over $[***] cumulative sales

  
 In the event that the
royalty paid by Dade Behring to its licensor is reduced by the licensor, the royalty paid by HemoSense hereunder shall be reduced proportionately. 
  

	 	7.03	Contingent License. In the event that Dade Behring is unable or unwilling to manufacture rTF for HemoSense, Dade Behring will grant to HemoSense a royalty-bearing, worldwide
sublicense to manufacture the rTF itself. 

  

	VIII. 	Milestones 

  

	 	8.01	HemoSense shall meet the milestones set forth in Schedule D within the time frames (including grace periods) set forth therein. In the event that HemoSense does not meet the
milestones within such time periods, Dade Behring shall have the right to terminate this Agreement upon fifteen (15) days written notice. 

  

	IX.	Confidentiality 

  

	 	9.01	Confidential Information. HemoSense and Dade Behring understand and agree that provisions for confidentiality shall be governed by the relevant provisions of that
Confidential Disclosure Agreement, previously executed, attached hereto and incorporated herein as Schedule E. The provisions for confidentiality shall survive the termination of this Agreement. 

  

	X.	Term and Termination 

  

	 	10.01 	 Term. Unless sooner terminated pursuant to the terms of this Agreement hereof, the term of this Agreement, including the license granted hereunder, shall
commence on the Effective Date and shall continue for a period of five (5) years thereafter and shall be automatically renewed for successive one (1) year terms unless 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 6 

	 	 
written notice is given by the nonrenewing party to the other party ninety (90) days prior to the end of such term). 

  

	 	10.02 	Termination. This Agreement may be terminated by either party upon written notice to the other party in the event (a) of a material breach of the provisions of this Agreement
by the other party which has not been cured within sixty (60) days from the time of receipt of written notice of such breach, or (b) that a party becomes insolvent or makes a general assignment for the benefit of creditors, or a receiver is
appointed for it, and does not return to solvency within forty-five (45) days from the time of receipt of written notice. Dade Behring may immediately terminate this Agreement in the event that the License Agreement between Dade Behring and [***]
and [***] University or (in the event that the Edgington patent is the surviving patent) the Cross License Agreement between Dade Behring and [***] is terminated. Such termination for cause shall not relieve either party of any obligation accrued
hereunder prior to termination nor prevent the party not in default from pursuing any remedies for contract breach it may have, either at law or in equity. 

  

	 	10.03 	Wind-Up. Upon the termination of this Agreement, Dade Behring shall continue to honor HemoSense’s Orders for rTF up to the effective date of termination and for a period
of sixty (60) days thereafter, provided however that HemoSense pays for such rTF on the terms and conditions of this Agreement, and Dade Behring has not terminated pursuant to Section 9.02. 

  

	XI.	Miscellaneous 

  

	 	11.01 	Notices. Any notice required by this Agreement shall be deemed sufficient if sent by certified mail, postage prepaid, to the party to be notified at the address set forth on
the first page of this Agreement until notice of a different address is supplied. 

  

	 	11.02 	Entire Agreement. This Agreement is the entire agreement between the parties hereto, there being no prior or oral promises or representations not incorporated herein.

  

	 	11.03 	Applicable Law. This Agreement shall be governed by the substantive laws of the Commonwealth of Massachusetts without regard to conflict of law principles directing the
application of the law of another jurisdiction. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 7 

	 	11.04 	Amendments. No amendments or modifications of the terms of this Agreement shall be binding on either party unless reduced to writing and signed by authorized officers of the
parties. 

  

	 	11.05 	Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original for all purposes. 

  

	 	11.06 	No Waiver. A waiver by either party or a breach or violation of any provision of this Agreement will not constitute or be construed as a waiver of any subsequent breach or
violation of that provision or as a waiver of any breach or violation of any other provision of this Agreement. 

  

	 	11.07 	Mutuality. This Agreement has been drafted on the basis of mutual understanding and neither party shall be prejudiced as being the drafter thereof. 

 

	 	11.08 	Independent Contractors. The parties are acting as independent contractors and nothing contained herein shall be construed to create a joint venture, agency relationship or
partnership. 

  

	 	11.09 	Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their affiliates, but shall not be assignable by either party without the
prior written consent of the other, which shall not be unreasonably withheld. 

  

	 	11.10 	Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect or limit the validity or enforceability of any other provision hereof.

  

	 	11.11 	Force Majeure. Each of the parties hereto shall be excused from the performance of its obligations hereunder in the event performance of this Agreement is prevented by Force
Majeure. The party incurring a Force Majeure condition shall promptly notify the other party in writing that such condition exists. For purposes of this Agreement, Force Majeure is defined as causes beyond the control of HemoSense and Dade Behring,
including acts of God, regulations or law of any government, civil commotion, strikes, destruction of production facilities or material by fire, water, earthquake or storm, epidemics, failure of public utilities or common carriers, and shortage of
materials. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 8 

 IN WITNESS WHEREOF duly authorized officers of the parties hereto have set their hands the day and year
first above written. 
  

									
	 HEMOSENSE INC.
	 	 	 	 DADE BEHRING INC.

					
	By:	 	 /s/ Lawrence Cohen
	 	 	 	By:	 	 /s/ Illegible

					
	 Title:
	 	 CEO
	 	 	 	 Title:
	 	 Assistant Secretary

					
	 Date:
	 	 3/5/99
	 	 	 	 Date:
	 	 5 March 1999

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 9 

 Schedule A 
  

Storage Conditions: 
 Store at [***]C, avoid multiple freeze-thaw cycles. 
  
 Certificate of Analysis and Specification Sheet 
  
 for 
  
 [***]

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Schedule B 
  

[***] 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Schedule C 
  
 $[***] per milligram of rTF 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 10 

 AMENDMENT TO SUPPLY AND 
  
 LICENSE AGREEMENT 
  
 This AMENDMENT TO SUPPLY AND LICENSE AGREEMENT (“Amendment”) is made effective into this 5th day of May, 2003 (“Effective Date”), by and between HemoSense, Inc., a Delaware corporation with its principal offices at 600 Valley Way, Milpitas,
California (“HemoSense”) and Dade Behring Inc., a Delaware corporation, with offices at 1717 Deerfield Rd., Deerfield IL (“Dade Behring”). 
  

WHEREAS, HemoSense and Dade Behring entered into that Supply and License Agreement dated March 5, 1999 (the “Agreement”); and 
  
 WHEREAS, HemoSense and Dade Behring desire to extend the Agreement and
HemoSense desires to obtain a license from Dade Behring and Dade Behring desires to grant a license to HemoSense certain patents owned by Dade Behring relating to tissue factor as set forth on Exhibit A including any continuations,
continuations-in-part, divisionals, reexams or reissues of such patents, attached hereto and incorporated herein (the “DB Patents”), and Dade Behring and HemoSense desire to amend the Agreement under the following terms and conditions, and

  
 WHEREAS, HemoSense is proposing the sale of additional shares
of Series C Preferred Stock of HemoSense, Inc, in order to raise an additional $[***] (the “Financing”). 
  
 NOW, THEREFORE, in consideration of the promises contained herein and for other good and valuable consideration the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows: 
  
 1.
The terms and conditions of the Agreement shall be incorporated herein by reference and shall be and remain in full force and effect throughout the term of this Amendment, except as amended herein as follows. 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 1 

 2. The term of the Agreement shall continue until March 05, 2007. 
  
 3. As partial consideration to Dade Behring for licensing the DB Patents to
HemoSense, in the Financing, HemoSense shall issue Dade Behring [***] shares of HemoSense Series C-1 Preferred Stock. This issuance will represent Dade Behring’s full pro rata share of the Financing and will allow Dade Behring to maintain the
status of all of its Preferred Shares as though Dade Behring had participated in the Financing by making an investment in cash to the full extent of its pro rata share. 
  
 4. Paragraph 3.01 shall be deleted and replaced with the following: 
  
 Dade Behring shall sell rTF to HemoSense at $[***] per mg (the
“Price”). Every January 1st, Dade Behring shall have the right to raise the Price of rTF commensurate with
the medical CPI-U. Prices are FOB, HemoSense Inc., Milpitas, CA. HemoSense shall purchase all of its requirements for rTF for the HemoSense Point of Care Product from Dade Behring. 
  
 5. Paragraph 7.01 shall be amended by adding the following sentence after the first sentence: 
  
 Dade Behring hereby grants to HemoSense and HemoSense hereby accepts from
Dade Behring a worldwide royalty bearing right and license under the DB Patents to make, have made, sell or have sold the Point of Care Product for the term of this Agreement. Dade Behring agrees that during the term of this Agreement if Dade
Behring owns or controls other patents that have claims directed to rTF which are used in the current HemoSense Point of Care Product set forth in Exhibit B, such patents shall be included in the DB Patents. 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 2 

 6. Paragraph 7.02 shall be deleted and replaced with the following. HemoSense shall pay to Dade Behring
on a quarterly basis a royalty on the Net Revenues of the Point of Care Product made to a HemoSense Customer based upon the following schedule: 
  

			
	 [***]% up to
	  	$[***] cumulative sales
		
	 [***]%
	  	$[***] cumulative sales
		
	 [***]%
	  	over $[***] cumulative sales.

  
 HemoSense agrees that
in no event will HemoSense manipulate the price charged to a HemoSense Customer so that Dade Behring receives less than a royalty based on an arms length transaction between a HemoSense Customer and HemoSense. 
  
 7. Dade Behring and HemoSense agree that any of the compensation paid by
HemoSense as set forth in paragraph 7.02 above may be used to compensate Dade Behring for the past and future maintenance of the Patents. 
  
 8. Prior to March 5, 2007, HemoSense shall have the option to extend the term of the Agreement until the date of the last expiring Patent and DB Patent,
providing that HemoSense provides Dade Behring with an additional lump sum payment in the following manner: 
  

			
	 Either
	  	$2.0 million by March 5, 2004;
		
	 Or
	  	$2.25 million by March 5, 2005;
		
	 Or
	  	$2.5 million by March 5, 2006;
		
	 Or
	  	$2.75 million by March 5, 2007

  
 At the time of such
extension, the parties shall adjust the price for the supply of rTF to a fair market price, not to exceed $[***] per mg at the effective date of that renegotiated extension. 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 3 

 9. Section 11.09 of the Agreement shall be amended by adding the following sentence: 
  
 “No consent shall be required for the assignment of this Agreement by
HemoSense to a third party that acquires all or substantially all of the business of HemoSense, whether by purchase of assets, purchase of stock or otherwise.” 
  
 10. Section 10.02 of the Agreement shall be amended by adding the following sentence: 
  
 “HemoSense otherwise may terminate this Agreement on one year’s
written notice.” 
  
 10. Section 11.12 shall set forth below
shall be added to the Agreement: 
  
 11.12 If
after March 31, 2003, Dade Behring enters into an agreement with a third party in which agreement the third party is licensed under the DB Patents and the Patents and Dade Behring supplies to or causes such third party to be supplied with rTF, then
Dade Behring for each such agreement shall compare the terms as a whole of the third party agreement with the terms of this Agreement. If the terms of the third party agreement are more favorable than this Agreement, then Dade Behring shall offer
HemoSense the same terms of the third party agreement as of the effective date of the third party agreement. HemoSense shall have sixty (60) days from the date of receipt of the new offer in which to execute and return such agreement to Dade
Behring. It is understood that this paragraph shall apply only to straight patent licenses for only the DB Patents and the Patents in the field of point of care or self-test market and in the same licensed territory. As used herein, the term
“straight patent license agreement” shall mean a royalty-based license including at least the rights to 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 4 

 
make, use, sell and import licensed product and Dade Behring receives only cash and/or the right to receive a royalty as consideration for the license.
Examples of agreements that are not included within the definition of “straight patent license agreement” include but are not limited to cross-license agreements, co-marketing agreements, collaborative research and development agreements,
non-commercial license or non-commercial supply agreements, settlement agreements or such license or agreement to which Dade Behring becomes a party and in which a substantial part of the consideration running to Dade Behring is not just a cash
payment in the form of a royalty or initial fee. 
  
 IN WITNESS
WHEREOF the authorized representatives of the parties have executed this Amendment as of the date first written above. 
  

							
	 HEMOSENSE INC.
	 	 	 	 DADE BEHRING INC.
	 	 
				
	 /s/ J. D. Merselis
	 	 	 	 /s/ [***]
	 	 5/5/03

	 J. D. Merselis
	 	 	 	 [***]
	 	 
	 Pres. & CEO
	 	 	 	 V.P., Technology Assessment
	 	 
	 Title:
	 	 	 	 Title:
	 	 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 5 

 Exhibit A to the Amendment to Supply and License Agreement between HemoSense Inc. and Dade Behring Inc.

  
 EP Patent No. [***] and foreign equivalents 
 “Preparation of prothrombin time reagents from recombinant human tissue factor and synthetic phospholipids” 
  

											
	 Country

	 	 Status

	 	 Application Number

	 	 Filing Date

	 	 Patent Number

	 	 Issue Date

	Australia	 	Granted	 	[***]	 	[***]	 	[***]	 	[***]
	Canada	 	Granted	 	[***]	 	[***]	 	[***]	 	[***]
	Japan	 	Allowed	 	[***]	 	[***]	 	 	 	 
	New Zealand	 	Granted	 	[***]	 	[***]	 	[***]	 	[***]
	USA*	 	Abandoned	 	[***]	 	[***]	 	 	 	 
	USA	 	Granted	 	[***]	 	[***]	 	[***]	 	[***]
	WO	 	Nat.Phase	 	[***]	 	[***]	 	 	 	 
						
	Europe:	 	Granted	 	[***]	 	[***]	 	[***]	 	[***]

  
 European designated countries:
Austria, Belgium, Denmark, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Netherlands, Spain, Sweden, Switzerland 
  

	*	Priority Application 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 1/1 

 Exhibit B 
  
 The HemoSense INRatio(tm) system consists of a meter and disposable test strips used to test Prothrombin Time (PT). The disposable test strips listed below incorporate
the Dade Behring recombinant tissue factor of this agreement. 
  
 INRatio Test
Strips - Box of 12 – Catalog #0100071 
 INRatio Test Strips - Bulk Pack of 48 – Catalog #0100139 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 SECOND AMENDMENT TO SUPPLY AND 
  
 LICENSE AGREEMENT 
  
 This SECOND AMENDMENT TO SUPPLY AND LICENSE AGREEMENT (“Amendment”) is made effective into this 3rd Day of June, 2004 (“Effective Date”), by and between HemoSense, Inc., a Delaware corporation with its principal
offices at 600 Valley Way, Milpitas, California (“Hemosense”) and Dade Behring Inc., a Delaware corporation, with offices at 1717 Deerfield Rd., Deerfield, IL (“Dade Behring”). 
  
 WHEREAS, HemoSense and Dade Behring entered into that Supply and License
Agreement dated March 5, 1999 (the “Agreement”) and amended on May 5th, 2003 (the “Amendment”);
and 
  
 WHEREAS, HemoSense is proposing the sale of additional
shares of Series C Preferred Stock of HemoSense, Inc., in order to raise an additional $[***] (the “2004 Financing”); and 
  
 WHEREAS, Dade Behring desires to maintain its pro rata share of C-2 Preferred Stock; and 
  
 WHEREAS, Dade Behring and Hemosense desire to amend the Agreement and
Amendment under the following terms and conditions. 
  
 NOW,
THEREFORE, in consideration of the promises contained herein and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  
 1. The terms and conditions of the Agreement and the Amendment shall be
incorporated herein by reference and shall be and remain in full force and effect, except as amended herein as follows. 
  
 2. HemoSense shall issue Dade Behring 357,570 shares of HemoSense Series C-2 Preferred Stock (the “shares”). This issuance will represent Dade

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 1 

 
Behring’s full pro rata share of the financing, and will allow Dade Behring to maintain the status of all of its Preferred Shares as though Dade Behring
had participated in the Financing by making an investment in cash to the full extent of its pro rata share. 
  
 3. In consideration for issuing the shares, HemoSense shall have a credit against earned royalties on Net Revenues for the Point of Care Product,
commencing July 1, 2004 in the amount of $1,025,000 (the “Credit”). 
  
 4. HemoSense shall provide Dade Behring with quarterly reports of Net Revenue and shall include the amount of royalty that would have been paid (if not for the credit) in the report. The report will also include the
amount of Credit remaining. 
  
 5. Under no circumstance will Dade
Behring be required to refund or pay HemoSense for any unused Credit. 
  
 IN WITNESS WHEREOF the authorized representatives of the parties have executed this Amendment as of the date first written above. 
  

					
	 HEMOSENSE INC.
	 	 	 	 DADE BEHRING INC.

			
	 /s/ J. D. Merselis
	 	 	 	 /s/ [***]

	 J. D. Merselis
	 	 	 	 [***]

	 Pres. & CEO
	 	 	 	 V.P. Technology Assessment

	 Title
	 	 	 	 Title

  
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 2Consulting Agreement dated May 17, 2002

 Exhibit 10.14 
  
 CONSULTING AGREEMENT 
  
 This agreement (“Agreement”) is dated May 17, 2002 (“Effective Date”) and is by and between HemoSense, Inc., a Delaware corporation
having a place of business at 600 Valley Way Milpitas, CA, 95035 USA (“Company”) and Innovative Medical Product Consultants, GmbH, a business organized and existing under the laws of Germany and having a place of business at Bonnerstrasse
528, 50968 Cologne, Germany (referred to herein as either “Consultant” or “IMedPro”). 
  
 RECITALS 
  
 The Company is engaged in the research, development, manufacture and marketing of certain medical diagnostic devices including, but not limited to, devices for the measurement of blood clotting and anticoagulation dosing
(“Company’s Business”); 
  
 The Consultant is a
business having employees and experience pertaining to clinical and regulatory affairs of medical products; and 
  
 The Company desires to retain the Consultant to provide consulting services to the Company. 
  
 AGREEMENT  
  

	I.	SERVICES 

  
 For the term of this Agreement, the Consultant shall: 
  

	 	A.	Provide the Company’s European Operations focused on the conduct of a German reimbursement trial to be conducted at 3-5 centers. These activities include:

  

	 	1.	Performing all necessary activities to initiate, conduct, and close this trial in the German centers identified by Company. 

  

	 	2.	Providing product feedback to the company based on the European experience. 

  

	 	3.	Facilitating data return to the coordinating center and to company by the participating centers. 

  

	 	4.	Maintaining center contact. 

  

	 	5.	Outside of product feedback and the efforts needed to perform the clinical trials, Consultant will not be conducting additional marketing, sales or distribution efforts for the
Company under this plan. 

  

	 	B.	Perform all necessary activities in Germany to be able to import, store, and use the Company product at the centers participating in the trial. 

  

	 	C.	Assist the Company and the coordinating center in preparation of the clinical report of the trial. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 1 

	II.	COMPENSATION 

  

	 	A.	For services provided by this Agreement the Company hereby grants to the Consultant a one-time to purchase 50,000 (fifty thousand) shares (the “Warrants”) of the
Company’s $.01 par value common stock (the “Common Stock”) (as adjusted from time to time upon the occurrence of any subdivision, stock split, combination or change of Common Stock into different number of shares of the same or any
other class or classes of shares, Company’s Warrant Agreement is attached hereto as Appendix A) at an exercise price of $0.20 per share. The options shall vest upon completion of certain milestones as follows: 

  

	 	1.	50% at Effective Date; 

	 	2.	50% upon completion of the trial described above. 

  
 In the event of material change of control, 100% of unvested shares shall immediately vest. In the event of termination of this Agreement by the Company
without cause under Section V (B)(2), 50% of any unvested shares shall immediately vest. The grant, vesting and other terms of the warrant grant hereunder shall be in accordance with the Warrant to Purchase Common Shares of HemoSense attached hereto
as Appendix A – the terms of which shall control in the event of conflict with any other terms of this Section II (B). 
  

	 	B.	The Company will reimburse the Consultant for customary, reasonable and necessary expenses incurred by the Consultant pursuant to this Agreement. Expenses shall be billed at actual
cost with 5% mark-up. Consultant will provide a monthly billing to the Company of all such expenses with detail sufficient to describe such expenses. The Consultant will retain records and receipts of such expenses. Payments for such expenses are
due 30 days following invoice. As a retainer for such expenses, the Company shall transfer US$67,000 (estimated 3 months forward expenses per budget attached in Appendix B) to Consultant immediately following execution of this Agreement. Appendix B
is a current estimate of expense to be incurred under this Agreement. 

  

	 	C.	The Consultant is an independent contractor and not an employee of the Company and has no authority to bind the Company to any contract or agreement. The Consultant is not entitled
to participate in benefits available to employee’s of the Company and is responsible for the payment of all income, employment or other taxes which may arise by reason of this Agreement. This Agreement is personal between the parties and no
organization with which the Consultant is associated is a party to this Agreement. 

  

	 	D.	The compensation recited herein is calculated as a present best estimate of value services provided by the Consultant to the Company. In the event the Consultant concludes that the
effort required by this Agreement is significantly greater than presently contemplated (or if the Company concludes the value of the services is significantly less than that presently contemplated), either party may request an appropriate
prospective modification to this Agreement. In the event the parties cannot agree, a party may terminate in accordance with Section V (B)(3). 

  

	III.	CONFIDENTIALITY 

  

	 	A.	 All information or data received by the Consultant from the Company and pertaining to the Company’s Business or derived or generated by the Consultant 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 2 

	 	 
while performing services under this Agreement shall be deemed the confidential information of the Company. Information shall not be deemed to be
confidential if: 

  

	 	(a)	it already was in the Consultant’s possession prior to disclosure by the Company; 

  

	 	(b)	it is or later becomes part of the public domain through no fault of the Consultant; or 

  

	 	(c)	it is lawfully received from a third party having no obligations of confidentiality to the Company. 

  

	 	B.	During the term of this Agreement and for one year thereafter, the Consultant will not disclose or use confidential information without the express written consent of the Company.

  

	 	C.	Company has no obligation to disclose confidential information to the Consultant and the nature and amount of any such disclosure shall be at the sole discretion of the Company.

  

	IV.	INVENTIONS 

  

	 	A.	All information or data derived or generated by the Consultant while performing services under this Agreement shall be the property of the Company. 

  

	 	B.	The term “Intellectual Property” means all inventions (patentable or unpatentable), discoveries, know-how or works of authorship made, conceived, authored or developed
(either alone or jointly with others) by the Consultant during the term of this Agreement and related to the Company’s Business or the demonstrably anticipated future product development concepts of the Company and which result from any work or
services the Consultant performs for the Company or from using confidential information of the Company. 

  

	 	C.	All Intellectual Property (including any “works for hire” under the copyright laws of the United States) is the sole and exclusive property of the Company and the
Consultant hereby assigns all such Intellectual Property to the Company. The Consultant agrees to cooperate with the Company, at the Company’s expense, in all efforts of the Company (including the preparation and filing of patent applications)
to perfect patent rights on any such Intellectual Property in the United States or abroad and to execute documents necessary to record the Company’s ownership of such rights with any government body including the United States Patent and
Trademark Office. 

  

	 	D.	The obligations to assign Intellectual Property to the Company shall not apply to any invention for which no equipment, supplies, facility or trade secret information of the Company
was used and which was developed entirely on the Consultant’s own time, and (1) which does not relate (a) directly to the business of the Company or (b) to the Company’s actual or demonstrably anticipated research or development, or (2)
which does not result from any work performed by the Consultant for the Company. 

  

	 	E.	 Recognizing that other individuals associated with Company may jointly or independently invent subject matter related to inventions conceived or reduced to practice
by the Consultant, the parties agree that the Company shall in its sole discretion determine the proper identity of inventors named on any patent 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 3 

	 	 
application based upon the Company’s investigation and determination of relevant information including, but not limited to, dates of conception, dates
of reduction to practice or diligence in reduction to practice. 

  

	V.	TERMINATION 

  

	 	A.	The term of this Agreement commences with the Effective Date and continues for three years or the completion of the milestones listed above, whichever is shorter.

  

	 	B.	This Agreement may be terminated as follows: 

  

	 	1.	The Company may terminate this Agreement immediately upon notice to the Consultant in the event the Consultant is unwilling or unable to perform services for any two consecutive
quarters. 

  

	 	2.	Either party may terminate this Agreement upon thirty days written notice to the other party in the event of any material breach of this Agreement by such other party and where such
breach remains uncured after such thirty-day period. 

  

	 	3.	Either party may terminate this Agreement upon 90 days notice to the other party. 

  

	 	C.	The obligations arising under Sections III and IV and any obligation to pay the Consultant for services or expenses incurred and not yet paid or reimbursed shall survive any
termination or expiration of this Agreement. 

  

	VI.	DISPUTES 

  

	 	A.	The parties intend to make reasonable effort to amicably resolve any disputes pertaining to this Agreement. 

  

	 	B.	Any unresolved disputes shall be subject to personal jurisdiction (hereby admitted) of the courts of the State of California and this Agreement will be interpreted according to the
laws of that State. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 4 

									
	AGREED TO BY:	 	 	 	 
			
	HEMOSENSE, INC.	 	 	 	 INNOVATIVE MEDICAL
 PRODUCT
CONSULTANTS,
 GMBH

					
	 By:
	 	 /s/ Dale Clendon
	 	 	 	 By:
	 	 /s/ Gregory M. Ayers

	 Its
	 	 SVP Business Development
	 	 	 	 Its
	 	 General Manager

	 Date:
	 	 5/17/02
	 	 	 	 Date:
	 	 5 – 17 – 2002

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 5 

 APPENDIX A 
 HemoSense Common Stock Warrant Agreement 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 6 

 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION UNLESS THE TRANSFER IS IN ACCORDANCE WITH RULE 144 OR SIMILAR RULE OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY
ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
  
 STOCK PURCHASE WARRANT 
  
 To Purchase Shares of Common Stock of 
  
 HEMOSENSE, INC. 
  
 THIS CERTIFIES that, for value received, Innovative Medical Product Consultants, (the “Investor”), is entitled, upon the terms and
subject to the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to May 17, 2005 (the “Termination Date”), but not thereafter, to subscribe for and purchase, from HemoSense, Inc., a Delaware
corporation (the “Company”), up to 50,000 shares of Common Stock (the “Shares”) on the terms set forth herein. 
  
 The per share exercise price of this Warrant (the “Exercise Price”) shall be $0.20. Upon the date hereof, fifty percent (50%) of the Shares
shall be exercisable. At such time as an officer of the Company certifies in writing that the clinical trial described in that certain Consulting Agreement of date even herewith between the Company and the Investor (the “Consulting
Agreement”) is completed, the remaining fifty percent (50%) of the Shares shall become exercisable. In the event of a transaction described in Section 10(a) hereof, all then unvested Shares shall become exercisable prior to the closing of such
transaction. In the event that this Agreement is terminated by the Company pursuant to Section [V(B)(3)] of the Consulting Agreement, fifty percent (50%) of any then unvested Shares shall become exercisable. 
  
 1. Title to Warrant. Prior to the expiration hereof and subject to
compliance with applicable laws, this Warrant and all rights hereunder are transferable, in whole or in part, at the office or agency of the Company, referred to in Section 2 hereof, by the holder hereof in person or by duly authorized attorney,
upon surrender of this Warrant together with the Assignment Form annexed hereto properly endorsed. 
  
 2. Exercise of Warrant. The purchase rights represented by this Warrant are exercisable by the registered holder hereof, in whole or in part, at
any time before the close of business on the Termination Date by the surrender of this Warrant and the Notice of Exercise form annexed hereto duly executed at the office of the Company, and upon payment of the purchase price of the Shares 

 
thereby purchased (by cash or by check or bank draft payable to the order of the Company or by cancellation of indebtedness of the Company to the holder
hereof, if any, at the time of exercise in an amount equal to the purchase price of the Shares thereby purchased); whereupon the holder of this Warrant shall be entitled to receive a certificate for the number of shares of Common Stock so purchased.

  
 3. Right to Convert Warrant. The registered holder
hereof shall have the right to convert this Warrant, by the surrender of this Warrant and the Notice of Conversion form annexed hereto duly executed at the office of the Company in Irvine, California (or such other office or agency of the Company as
it may designate by notice in writing to the registered holder hereof at the address of such holder appearing on the books of the Company), in whole but not in part, at any time before the close of business on the Termination Date, into the Shares
as provided for in this Section 3. Upon exercise of this conversion right, the holder hereof shall be entitled to receive that number of Shares equal to the quotient obtained by dividing [(A - B)(X)] by (A), where: 
  

	 	(A)	=  the Fair Market Value (as defined below) of one Share on the date of conversion of this Warrant. 

  

	 	(B)	=  the Exercise Price for one Share under this Warrant. 

  

	 	(X)	=  the number of Shares issuable upon exercise of this Warrant. 

  
 If the above calculation results in a negative number, then no Shares shall be issued or issuable upon conversion of this Warrant. 
  
 “Fair Market Value” of a Share shall mean: 
  

	 	(a)	if the conversion right is being exercised upon the occurrence of a transaction specified in paragraph 10(a) hereof, the value of the consideration (determined as set forth in the
Company’s Amended and Restated Certificate of Incorporation) to be received pursuant to such transaction by the holder of one Share issuable upon exercise of this Warrant, 

  

	 	(b)	if the conversion right is being exercised upon the occurrence of the Company’s initial public offering, the initial public offering price per share (before deducting
underwriting commissions and discounts and offering expenses), 

  

	 	(c)	if the conversion right is being exercised after, and not in connection with the Company’s initial public offering, and: 

  
 (i) if traded on a securities exchange, the fair market value shall be
deemed to be the average of the closing prices of the securities on such 
  

 -2- 

 exchange over the 30-day period ending three (3) days before the day the current fair market value of the
securities is being determined; or 
  
 (ii) if actively traded
over-the-counter, the fair market value shall be deemed to be the average of the closing bid or sale prices (whichever are applicable) over the 30-day period ending three (3) days before the day the current fair market value of the securities is
being determined; 
  

	 	(d)	in all other cases, the fair value as determined in good faith by the Company’s Board of Directors. 

  
 Upon conversion of this Warrant, the registered holder hereof shall be entitled to receive a certificate for the number of
Shares determined as aforesaid. 
  
 4. Issuance of Stock; No
Fractional Shares or Scrip. Certificates for the stock purchased hereunder or issuable upon conversion hereof shall be delivered to the holder hereof promptly after the date on which this Warrant shall have been exercised or converted as
aforesaid. The Company covenants that all Shares which may be issued upon the exercise of rights represented by this Warrant will, upon exercise of the rights represented by this Warrant, be fully paid and nonassessable and free from all taxes,
liens and charges in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). The Company agrees that, if at the time of the surrender of this Warrant and exercise of the rights
represented hereby, the holder hereof shall be entitled to exercise such rights, the Shares so issued shall be and be deemed to be issued to such holder as the record owner of such Shares as of the close of business on the date on which this Warrant
shall have been exercised or converted as aforesaid. No fractional shares or scrip representing fractional shares shall be issued upon the exercise or conversion of this Warrant. With respect to any fraction of a Share called for upon the exercise
or conversion of this Warrant, an amount equal to such fraction multiplied by the then current price at which each Share may be purchased hereunder shall be paid in cash to the holder of this Warrant. 
  
 5. Charges, Taxes and Expenses. Issuance of certificates for the
Shares upon the exercise or conversion of this Warrant shall be made without charge to the holder hereof for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the holder of this Warrant or in such name or names as may be directed by the holder of this Warrant; provided, however, that in the event certificates for
Shares are to be issued in a name other than the name of the holder of this Warrant, this Warrant when surrendered for exercise or conversion shall be accompanied by the Assignment Form attached hereto duly executed by the holder hereof; and
provided further, that upon any transfer involved in the issuance or delivery of any certificates for the Shares, the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto. 
  

 -3- 

 6. No Rights as Stockholders. This Warrant does not entitle the holder hereof to any voting rights
or other rights as a stockholder of the Company prior to the exercise or conversion thereof. 
  
 7. Exchange and Registry of Warrant. This Warrant is exchangeable, upon the surrender hereof by the registered holder at the above-mentioned office or agency of the Company, for a new Warrant of like tenor and
dated as of such exchange. 
  
 The Company shall maintain at the
above-mentioned office or agency a registry showing the name and address of the registered holder of this Warrant. This Warrant may be surrendered for exchange, transfer or exercise, in accordance with its terms, at such office or agency of the
Company, and the Company shall be entitled to rely in all respects, prior to written notice to the contrary, upon such registry. 
  
 8. Loss, Theft, Destruction or Mutilation of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender and
cancellation of this Warrant, if mutilated, the Company will make and deliver a new Warrant of like tenor and dated as of such cancellation, in lieu of this Warrant. 
  
 9. Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a legal holiday. 
  
 10. Early Termination and Dilution. 
  
 (a) Merger, Sale of Assets, etc. If at any time after the date hereof
the Company proposes to merge with or into any other corporation, effect a consolidation or reorganization with or into any other entity, or sell or convey all or substantially all of its assets to any other entity, in a transaction in which the
stockholders of the Company shall receive cash or publicly traded securities in exchange for their shares of stock in the Company pursuant to such transaction, then the Company shall give the holder of this Warrant written notice of such impending
transaction not later than thirty (30) days prior to the stockholders’ meeting called to approve such transaction, or thirty (30) days prior to the closing of such transaction, whichever is earlier, and shall also notify the holder of this
Warrant of the final approval of such transaction. The first of such notices shall describe the material terms and conditions of the impending transaction, and the Company shall thereafter give the holder of this Warrant prompt notice of any
material changes. If the Warrant has not been exercised or converted by the closing of such transaction it shall terminate. 
  
 (b) Reclassification, etc. If the Company at any time shall, by subdivision, combination or reclassification of securities or otherwise, change any
of the securities to which purchase rights under this Warrant exist into the same or a different number of securities of any class 

  

 -4- 

 
or classes, this Warrant shall thereafter be to acquire such number and kind of securities as would have been issuable as the result of such change with
respect to the securities which were subject to the purchase rights under this Warrant immediately prior to such subdivision, combination, reclassification or other change. If the Shares issuable upon the exercise of this Warrant are subdivided or
combined into a greater or smaller number of the Shares, the purchase price under this Warrant shall be proportionately reduced in case of subdivision of shares or proportionately increased in the case of combination of shares, in both cases by the
ratio which the total number of the Shares to be outstanding immediately after such event bears to the total number of the Shares outstanding immediately prior to such event. 
  
 (c) Cash Distributions. No adjustment on account of dividends on the Shares issuable upon the
exercise of this Warrant will be made to the purchase price under this Warrant. 
  
 (d) Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its
authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall
constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Shares upon the exercise of the purchase rights under this Warrant. 
  
 (e) Conversion Price Adjustments. The rate at which
the Shares are convertible into shares of Common Stock of the Company is subject to adjustment as set forth in the Company’s Restated Articles of Incorporation. Any adjustment to the conversion rate of the Shares issuable upon the exercise of
this Warrant effected prior to any exercise or conversion of this Warrant shall apply to any Shares thereafter issued pursuant to the terms hereof. 
  
 11. Restrictions on Transferability of Securities. 
  
 (a) Restrictions on Transferability. This Warrant and the Shares issuable upon exercise of this Warrant (collectively the
“Securities”) shall not be sold, assigned, transferred or pledged except upon the conditions specified in this Section 11, which conditions are intended to ensure compliance with the provisions of the Securities Act of 1933, as amended
(the “Securities Act”). Each holder of any of the Securities will cause any proposed purchaser, assignee, transferee, or pledgee of the Securities held by such holder to agree to take and hold such Securities subject to the provisions and
upon the conditions specified in this Section 11. 
  
 (b) Restrictive Legend. Each certificate representing the Securities and any other securities issued in respect of the Securities upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall
(unless otherwise permitted by the provisions of Section 11(c) below) be stamped or otherwise imprinted with a legend in the following form (in addition to any legend required under applicable state securities laws): 
  

 -5- 

 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION UNLESS THE TRANSFER IS IN ACCORDANCE WITH RULE 144 OR SIMILAR RULE OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL
REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
  
 Each holder of Securities and each subsequent transferee (hereinafter collectively referred to as a “Holder”) consents to the Company making a
notation on its records and giving instructions to any transfer agent of the Securities in order to implement the restrictions on transfer established in this Section 11. 
  
 (c) Notice of Proposed Transfers. Each Holder of a certificate representing the Securities, by acceptance thereof,
agrees to comply in all respects with the provisions of this Section 11(c). Prior to any proposed sale, assignment, transfer or pledge of any Securities (other than (i) a transfer not involving a change in beneficial ownership, (ii) in transactions
involving the distribution without consideration of Securities by a Holder to any of its partners, or retired partners, or to the estate of any of its partners or retired partners, (iii) a transfer to an affiliated fund, partnership or company,
which is not a competitor of the Company, subject to compliance with applicable securities laws or (iv) transfers in compliance with Rule 144, so long as the Company is furnished with satisfactory evidence of compliance with such Rule), unless there
is in effect a registration statement under the Securities Act covering the proposed transfer, the Holder thereof shall give written notice to the Company of such Holder’s intention to effect such transfer, sale, assignment or pledge. Each such
notice shall describe the manner and circumstances of the proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied, at such Holder’s expense, by either (i) an opinion of counsel (who shall, and whose opinion
shall be, addressed to the Company and reasonably satisfactory to the Company) to the effect that the proposed transfer of the Securities may be effected without registration under the Securities Act or (ii) a “no action” letter from the
Securities and Exchange Commission (the “Commission”) to the effect that the transfer of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto,
whereupon the Holder of such Securities shall be entitled to transfer such Securities in accordance with the terms of the notice delivered by such Holder to the Company. Each certificate evidencing the Securities transferred as above provided shall
bear, except if such transfer is made pursuant to Rule 144, the appropriate restrictive legend set forth in Section 11(b) above, except that such certificate shall not bear such restrictive legend if in the opinion of counsel for such Holder and in
the opinion of counsel for the Company such legend is not required in order to establish compliance with any provision of the Securities Act. 
  
 (d) Removal of Restrictions on Transfer of Securities. Any legend referred to in Section 11(b) hereof stamped on a certificate evidencing the
Securities and the stock transfer instructions and record notations with respect to the Securities shall be removed and the Company shall issue a certificate without such legend to the Holder of the Securities if the Securities are 

  

 -6- 

 
registered under the Securities Act, or if such Holder provides the Company with an opinion of counsel (which may be counsel for the Company) reasonably
satisfactory to the Company to the effect that a public sale or transfer of such security may be made without registration under the Securities Act or such Holder provides the Company with reasonable assurances, which may, at the option of the
Company, include an opinion of counsel (which may be counsel for the Company) reasonably satisfactory to the Company, that such security can be sold pursuant to paragraph (k) of Rule 144 (or any successor provision) under the Securities Act.

  
 12. Investment Representations of the Investor. With
respect to the acquisition of any of the Securities, the Investor hereby represents and warrants to the Company as follows: 
  
 (a) Experience. The Investor has substantial experience in evaluating and investing in private placement transactions of securities in companies
similar to the Company so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. The Investor is an “accredited investor” within the meaning of Regulation D
promulgated under the Securities Act. 
  
 (b) Investment.
The Investor is acquiring the Securities for investment for its own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof. The Investor understands that the Securities have not been,
and will not be, registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment intent
and the accuracy of the Investor’s representations as expressed herein. 
  
 (c) Rule 144. The Investor acknowledges that the Securities must be held indefinitely unless subsequently registered under the Securities Act, or unless an exemption from such registration is available. The
Investor is aware of the provisions of Rules 144 and 144A promulgated under the Securities Act that permit limited resale of securities purchased in a private placement subject to satisfaction of certain conditions. 
  
 (d) No Public Market. The Investor understands that no public market
now exists for any of the securities issued by the Company and that the Company has made no assurances that a public market will ever exist for the Securities. 
  

(e) Access to Data. The Investor has had an opportunity to discuss the Company’s business, management and financial affairs with the
Company’s management and has also had an opportunity to ask questions of the Company’s officers, which questions were answered to its satisfaction. 
  
 13. Notices. 
  
 (a) Notice of Public Offering. If at any time prior to the exercise or conversion of this Warrant in full the Company shall determine to effect a
registered public offering of its 

  

 -7- 

 
securities, then the Company will give the holder of this Warrant at least thirty (30) days prior written notice of the proposed effective date of the
transaction. 
  
 (b) Notice of Record Date. If at any time
prior to the exercise or conversion of this Warrant in full the Company takes a record of the holders of the Company’s stock for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, any
right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities or property, or to receive any other right, the Company will give to the holder of this Warrant, at least thirty (30) days prior to the
date specified therein, written notice specifying the date on which any such record is to be taken for the purpose of such dividend, distribution or right, and the amount and character of such dividend, distribution or right. 
  
 14. Miscellaneous. 
  
 (a) Issue Date. The provisions of this Warrant shall be construed and
shall be given effect in all respect as if it had been issued and delivered by the Company on the date hereof. This Warrant shall be binding upon any successors or assigns of the Company. This Warrant shall constitute a contract under the laws of
the State of Delaware and for all purposes shall be construed in accordance with and governed by the laws of said state. 
  
 (b) Waivers and Amendments. With the written consent of the Company and the Investor, the obligations of the Company and the right of the Investor
may be waived (either generally or in a particular instance, either retroactively or prospectively and either for a specified period of time of indefinitely), and with the same consent the Company and the Investor may enter into a supplementary
agreement for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Warrant. 
  
 (c) Notices. All notices and other communications required or permitted to be given under this Warrant shall be in writing and shall be deemed
effectively given upon personal delivery, delivery by nationally recognized courier or upon deposit with the United States Post Office (by first class mail, postage prepaid) addressed as follows: (i) if to the Company, at its principal place of
business, and (ii) if to the Investor, at Bonnerstrasse 528, 50968 Cologne, Germany. 
  
 (d) Survival. The provisions of Section 11 hereof shall survive the exercise or conversion of this Warrant and shall remain in effect until such time as the Investor no longer holds Securities. 
  
  

 -8- 

 IN WITNESS WHEREOF, HemoSense, Inc. has caused this Warrant to be executed by its officers thereunto duly
authorized. 
  
 Dated: May 17, 2002 
  

			
	HEMOSENSE, INC.
		
	By:	 	/s/ DALE CLENDON
		
	Name:	 	Dale Clendon
	Title:	 	SVP Business Development

  
  
  
 Agreed and Accepted: 
  

			
	INVESTOR
		
	By:	 	/s/ GREGORY M. AYERS
		
	Name:	 	Gregory M. Ayers
	Title:	 	General Manager

  
  
  
  
  

 NOTICE OF EXERCISE 
  
 To: HemoSense, Inc. 
  
 (1) The undersigned hereby elects to purchase
                         shares of Common Stock of HemoSense, Inc. pursuant to the terms of the attached Warrant, and
tenders herewith payment of the purchase price in full, together with all applicable transfer taxes, if any. 
  
 (2) Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is
specified below: 
  

	
	
	

	(Name)
	
	

	(Address)

  
 (3) The
undersigned represents that the aforesaid shares of Common Stock are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no
present intention of distributing or reselling such shares. 
  

			
		
	
	 	

	 (Date)
	 	 (Signature)

  
  

 NOTICE OF CONVERSION 
  
 To: HemoSense, Inc. 
  
 (1) The undersigned hereby elects to convert the attached Warrant into such number of shares of Common Stock of HemoSense, Inc. as is determined pursuant
to Section 3 of such Warrant, which conversion shall be effected pursuant to the terms of the attached Warrant. 
  
 (2) Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is
specified below: 
  
  

	
	
	

	(Name)
	
	

	(Address)

  
 (3) The undersigned
represents that the aforesaid shares of Common Stock are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present
intention of distributing or reselling such shares. 
  
  

			
		
	
	 	

	 (Date)
	 	 (Signature)

  
  

 ASSIGNMENT FORM 
  
 (To assign the foregoing warrant, execute 
 this form and supply required information. 
 Do not use this form to purchase shares.) 
  
 FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to 
  

 (Please Print) 
  
 whose address
is                                       
                                        
                                        
                                        
                              
 (Please Print) 
  

  

			
	
	 Dated:
                                        
        , 20                    

	
	 Holder’s Signature:
                                       
             

	
	Holder’s Address:
                                        
            
	
	 
	 	 	 

  
  
  
  

	
	
	Signature
Guaranteed:                                      
                                        
                                        
                                        
                  
	 

  
 NOTE: The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]